SavedAdd your journal

Journals / Clinical and Experimental Health Sciences / 2019 / Cilt: 9 - Sayı: 4

Antidepressant-Like Effects of Ceftriaxone in Chronic Unpredictable Mild Stress Model in Rats: The Importance of Reuptake Time of Glutamate

Damla BİNNETOĞLU
Feyza ARICIOGLU
Halil OZCAN
Ufuk OKKAY
Ahmet HACIMUFTUOGLU
Pages
294–299
Publication Date
2019-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Escitalopram treatment in CA3 region corrected the decrease in glutamate reuptake time which is consistent with the hypothesis that enhanced uptake of glutamate might have antidepressant-like effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to indicate the relationship between depression and glutamate, and to reveal the effect of escitalopram, an antidepressant, which is widely used in depression treatment and reuptake parameters of glutamate, and to treat depression with ceftriaxone, one of the beta lactam antibiotics which increased the number and activity of glutamate transporters.
📊
Key Findings & Data:Methods: In CUMS, rats subjected to series of different mild stressors in an unpredictable manner for 40 days.
💡
Conclusion & Impact:Escitalopram treatment in CA3 region corrected the decrease in glutamate reuptake time which is consistent with the hypothesis that enhanced uptake of glutamate might have antidepressant-like effects.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Beta lactam antibiotics · ceftriaxone · depression

Abstract

Objective: We aimed to indicate the relationship between depression and glutamate, and to reveal the effect of escitalopram, an antidepressant, which is widely used in depression treatment and reuptake parameters of glutamate, and to treat depression with ceftriaxone, one of the beta lactam antibiotics which increased the number and activity of glutamate transporters. Methods: In CUMS, rats subjected to series of different mild stressors in an unpredictable manner for 40 days. On the day 20 rats were divided in to groups such as CUMS, CUMS+Escitalopram and CUMS+Ceftriaxone. 4 weeks. Treatments were started at 2nd week of CUMS and continued for 21 days. Anhedonia and antidepressant effect were assessed by sucrose preference (SP), locomotor activity (LA), elevated plus maze (EPM) and forced swim test (FST) at the end of the experiment respectively. At the end of the experiment, behavioral tests were made, and glutamate reuptake time in CA3 (cornuammonis 3) brain region which are related with depression were measured by means of in vivo voltammetry technique. Results: Ceftriaxone treatment had an antidepressant-like effect. Escitalopram and ceftriaxone increased SP and locomotor activity, reduced immobility FST, forced swim and time spent in closed arms in EPM compared to CUMS group. In this in-vivo voltametric study, it was also observed that there was a significant decrease in glutamate reuptake time in depression. Conclusion: Escitalopram and ceftriaxone demonstrated antidepressant-like effects by reversing behavioral changes in CUMS model. Escitalopram treatment in CA3 region corrected the decrease in glutamate reuptake time which is consistent with the hypothesis that enhanced uptake of glutamate might have antidepressant-like effects.

🔖

Cite This Article

BİNNETOĞLU, D., ARICIOGLU, F., OZCAN, H., OKKAY, U., HACIMUFTUOGLU, A. (2019). Antidepressant-Like Effects of Ceftriaxone in Chronic Unpredictable Mild Stress Model in Rats: The Importance of Reuptake Time of Glutamate. Clinical and Experimental Health Sciences, Cilt: 9 - Sayı: 4, 294–299. https://ajindex.com/articles/481592

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 2001; 43(5): 411-23
  2. Kulkarni SK and Dhir A. Current investigational drugs for major depression, Expert Opin Investig Drugs 2009; 18(6): 767-88
  3. Lee TS, Quek SY and Krishnan KR. Molecular Imaging for Depressive Disorders, AJNR Am J Neuroradiol 2014; 35(6): 44-54
  4. Arciniegas DB, Anderson CA, Topkoff J, McAllister TW. Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment, Neuropsychiatr Dis Treat 2005; 1(4): 311–327
  5. Duman RS. Pathophysiology of depression and innovative treatments: remodelling glutamatergic synaptic connections, Dialogues in Clinical neuroscience 2014; 16: 11-27
  6. Zhu X, Ye G, Wang Z, Luo J, Hao X. Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats, Neuroscience Letters 2017; 639(3): 132–137
  7. Czéh B, Fuchs E, Wiborg O, Simong M. Animal models of major depression and their clinical implications, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016; 64: 293-310
  8. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation, Psychopharmacology 1997; 134(4): 319–329
  9. Willner P. Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS, Neuropsychobiology 2005; 52: 90–110
  10. Willner et al., Chronic mild stress-induced anhedonia: A realistic animal model of depression, Neuroscience & Biobehavioral Reviews 1992; 16 (4): 525-534
  11. Helena M. Abelaira HM, Reus GZ, Quevedo J. Animal models as tools to study the pathophysiology of depression, Rev Bras Psiquiatr 2013; 35(2): 112-120
  12. Deussing JM. Animal models of depression, Drug Discovery Today: Disease Models 2006; 3(4): 375-383
  13. Wiborg O. Chronic mild stress for modeling anhedonia, Cell and Tissue Research 2013; 354(1): 155–169
  14. Haapakoski R, Ebmeier KP, Aleniusc H,Kivimäki M. Innate and adaptive immunity in the development of depression: An update on current knowledge and technological advances, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016; 66: 63-72
  15. Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues ALS, Peluffo H, Kaster MP. NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings, Brain